Not Yet RecruitingNot Applicable

UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

United States50,000 participantsStarted 2026-08-31

Plain-language summary

This is a non-therapeutic clinical research biorepository protocol designed to obtain, store, and clinically annotate biospecimens from participants with hereditary cancers. Those biospecimens will be used to generate participant-derived tumor models that will serve as a resource to better understand hereditary cancers and develop new efficient therapies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Ability to understand and willingness to voluntarily sign a written informed consent document prior to any study-related assessments or procedures are conducted.
✓. Individuals 18 years of age or older on the day of signing informed consent.
✓. Individuals with solid tumor malignancy with germline or somatic cancer-associated mutations and/or Individuals with a family history or personal history of cancer.
✓. Must be planning to undergo one of the following procedures as part of their routine care (or as a research procedure under a UCSF-sponsored IIT protocol):
✓. Surgical resection
✓. Biopsy (open, incisional, excisional, punch, core needle, and/or fine needle aspiration (FNA) are all permitted)
✓. Paracentesis
✓. Thoracentesis

What they're measuring

Develop participant-derived tumor models of hereditary cancers

Timeframe: Up to 10 years

Trial details

NCT IDNCT06895681

SponsorUniversity of California, San Francisco

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2035-12-31

Contact for this trial

Phu Lam

877-827-3222 Phu.Lam@ucsf.edu

View on ClinicalTrials.gov More Solid Tumor trials